Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296491 · ClinicalTrials.gov registry record · Phase 4
Study Of Allergic Rhinitis In Patients Who Also Have Asthma
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 725
- Enrollment target
NCT00296491: Completed Phase 4 study, sponsored by GlaxoSmithKline.
NCT00296491 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 725 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (40% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00296491, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 725 participants
- Enrollment target
Study Summary
This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.
Primary Outcome
Endpoint was defined as the average of the data reported from the last week of treatment. Data collected by patient throughout the treatment period between visits. The peak expiratory flow rate measures how fast a person can breathe out (exhale) air. It is one of many tests that measure how well your airways work.
Interventions
- DRUG ADVAIR DISKUS
- DRUG fluticasone propionate/salmeterol (FSC)
- DRUG montelukast (MON)
- DRUG fluticasone propionate (FP)
- DRUG placebo nasal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 725 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
What the finished NCT00296491 record still lists
NCT00296491 is an interventional study that assigns participants to a tested intervention. The registered 725 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (40% higher).
The record links to 0 conditions, and to 5 interventions - of which ADVAIR DISKUS is the first listed.
NCT00296491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00296491 about?
NCT00296491 is a clinical study titled "Study Of Allergic Rhinitis In Patients Who Also Have Asthma". This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs u...
What is the current status of trial NCT00296491?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 725 participants. The study started on 2005-09. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00296491?
The interventions under investigation include: ADVAIR DISKUS (DRUG), fluticasone propionate/salmeterol (FSC) (DRUG), montelukast (MON) (DRUG), fluticasone propionate (FP) (DRUG), placebo nasal (DRUG).
Who is sponsoring clinical trial NCT00296491?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00296491's enrollment target sits among peer trials
725 114th of 2000 higher than 1,887 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT06731478 · 726 participants · Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia